ACET
Adicet Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.53
−0.88%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +16.9%
- EBIT
- +17.8%
- EPS
- +45.4%
- Free cash flow
- +15.2%
- Operating cash flow
- +13.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +43.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +0.2%
- EBIT
- +4.3%
- Net income
- +0.3%
- EPS
- +20.3%
- Free cash flow
- -3.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026